Trial Profile
Open Label Extension Study of AMX0035 in Patients With ALS
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Jun 2023
Price :
$35
*
At a glance
- Drugs Sodium phenylbutyrate/ursodoxicoltaurine (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Acronyms CENTAUR-OLE
- Sponsors Amylyx Pharmaceuticals
- 27 Apr 2023 Results of a post-hoc analysis assessing potential effect of placebo-to-active crossover on intent-to-treat overall survival results from the CENTAUR and its OLE trial; was performed utilizing an external, propensity score-matched, PB&TURSO-naive cohort from the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database as a historical control comparator presented at the 75th Annual Meeting of the American Academy of Neurology 2023
- 01 Aug 2022 Results of a survival analyses of data from CENTAUR and open label extension study published in the Muscle and Nerve
- 05 May 2022 Results presented in an Amylyx Pharmaceuticals media release.